Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares STAT3 and the tag parent-page.
Shares Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors, Robin Kate Kelley, KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma, The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma.
Shares KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma, The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma, Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers, A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors..
Shares Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer, Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers, A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC), Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer.
Shares Belfast Health and Social Care Trust HPB service, Derriford Hospital, University Hospitals Plymouth, King's College Hospital, London, Morriston Hospital, Swansea.
Shares Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer., Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer, An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy., Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.